JHEP Reports最新文献

{"title":"Genetic risk score correlates with immune profile and risk of HCC and cirrhosis development in Hispanics with MASLD","authors":"Siyu Fu , Zwier M.A. Groothuismink , Domingo Balderramo , Angelo Z. Mattos , Lisia Hoppe , Enrique Carrera , Javier Diaz-Ferrer , Jhon Prieto , Jesus M. Banales , Marco Arrese , Bettina E. Hansen , Andre Boonstra , José D. Debes","doi":"10.1016/j.jhepr.2025.101508","DOIUrl":"10.1016/j.jhepr.2025.101508","url":null,"abstract":"<div><h3>Background & Aims</h3><div>Genetic risk score and immune dysregulations have been separately associated with the development of hepatocellular carcinoma (HCC) and cirrhosis in the context of metabolic dysfunction-associated steatotic liver disease (MASLD). Latin America has the highest prevalence of MASLD worldwide. However, the relationship between genetic risk scores, immune dysregulation, and MASLD has not been explored.</div></div><div><h3>Methods</h3><div>We assessed SNPs of <em>PNPLA3</em> rs738409, <em>TM6SF2</em> rs58542926, <em>MBOAT7</em> rs641738, and <em>HSD17B13</em> rs72613567 in samples from a cohort of 972 Latin American individuals (HCC = 267, non-HCC = 705). The four SNPs were later combined into a genetic risk score and calculated in patients with MASLD (cirrhotic HCC = 133, cirrhosis = 242, non-cirrhotic liver disease (NCLD) = 113). A total of 28 cytokines were analyzed in a subgroup of these samples (cirrhotic HCC = 107, cirrhosis = 111).</div></div><div><h3>Results</h3><div>At an individual level, only <em>PNPLA3</em> GG genotype was associated with a significantly increased risk of MASLD-related HCC (odds ratio [OR]: 2.805, 95% CI: 1.083–7.264, <em>p</em> = 0.034) and cirrhosis (OR: 6.873, 95% CI: 3.293–14.35, <em>p</em> <0.001). When the four SNPs were combined into a genetic risk score, patients with a score of 6–8 had higher odds of MASLD-related HCC (OR: 3.603, 95% CI: 1.008–12.88, <em>p</em> = 0.049) and cirrhosis (OR: 13.12, 95% CI: 2.270–75.76, <em>p</em> = 0.004) compared with those with a score of 0–2. Cytokine profiles differed by genetic risk score in MASLD-related HCC and cirrhosis. Patients with HCC with high scores had lower levels of interferon-gamma and CCL8 (false discovery rate <0.05), whereas patients with cirrhosis with high scores showed higher matrix metallopeptidase 2 (MMP2) levels (false discovery rate <0.05).</div></div><div><h3>Conclusions</h3><div>In Latin America, genetic risk score 6–8 in patients is strongly associated with an increased risk of MASLD-related HCC and cirrhosis. Additionally, patients with HCC and cirrhosis showed distinct immune profiles across high and low genetic risk score groups.</div></div><div><h3>Impact and implications</h3><div>The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related hepatocellular carcinoma (HCC) and cirrhosis is rising, with Hispanics having the highest MASLD rates. However, large-scale studies examining the association between genetic risk score, immune profiles, and the progression of MASLD-related HCC and cirrhosis are still lacking. In our study, we found that patients with MASLD-related HCC and cirrhosis who had higher genetic risk score were more likely to show higher odds ratios compared with those with lower genetic risk score. Additionally, genetic risk scores were found to be associated with immune profiles, as reflected by cytokine levels. These findings could assist clinicians in ident","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 10","pages":"Article 101508"},"PeriodicalIF":7.5,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145019814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and active ingredients of digital behaviour change interventions for MASLD: A systematic review and meta-analysis","authors":"Hollie Smith ,&nbsp;Rebecca Livingston ,&nbsp;Kirsten Ashley ,&nbsp;Matthew Cooper ,&nbsp;Stuart McPherson ,&nbsp;Alison Innerd ,&nbsp;Kate Hallsworth ,&nbsp;Leah Avery","doi":"10.1016/j.jhepr.2025.101507","DOIUrl":"10.1016/j.jhepr.2025.101507","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver condition worldwide. Successful management relies on targeting changes in lifestyle behaviours. Digital behaviour change interventions present a scalable approach to lifestyle change. The aim of this systematic review was to determine the effectiveness and active ingredients of digital behavior change interventions for improving weight and liver-related outcome measures in patients with MASLD.</div></div><div><h3>Methods</h3><div>Five databases were searched up to 31 January 2025 for studies reporting on digital lifestyle behaviour change interventions for patients with MASLD. Data were meta-analysed or narratively synthesised depending on study design. Intervention content and features positively associated with changes in outcomes of interest were identified using promise analysis.</div></div><div><h3>Results</h3><div>Eleven studies involving 1,288 participants fulfilled the review criteria. Digital behavior change interventions were not effective for reducing weight (weighted mean difference [WMD] -2.07 kg [-6.08 to 1.94 kg]). Likewise, they did not lead to statistically significant improvements in alanine transaminase and aspartate transaminase (WMD -9.14 [-20.33 to 2.05] and WMD -5.81 [-12.96 to 1.35], respectively). Interventions varied in terms of mode of delivery (<em>e.g.</em> app and SMS), duration (1–11 months), and frequency of delivery (three times/week to continuous access). Promising intervention features/content included app-based delivery, ≥6-month duration, and self-monitoring of behaviour, feedback on outcomes, and social support.</div></div><div><h3>Conclusions</h3><div>Digital behaviour change interventions did not improve weight and liver-related outcomes measures in patients with MASLD. However, the inclusion of proposed specific intervention ingredients is likely to improve effectiveness.</div></div><div><h3>Impact and implications</h3><div>This review is the first of its kind to report on the effectiveness and active ingredients of digital behaviour change interventions for the management of MASLD. Although the interventions reviewed were not effective overall, specific features and content of those interventions were associated with effectiveness. These insights can be used to inform the development of new interventions or to optimise existing interventions that could improve effectiveness. Findings also suggest that digital behaviour change interventions are beneficial for a proportion of individuals, and future research should focus on identifying who those individuals are. Significant heterogeneity between interventions was evident in terms of mode of delivery, behavioural change content, duration, and frequency of delivery. To truly determine the effectiveness of digital behaviour change interventions for patients with MASLD, they should be systematically developed using behaviour chang","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 10","pages":"Article 101507"},"PeriodicalIF":7.5,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145019811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright and information","authors":"","doi":"10.1016/S2589-5559(25)00181-8","DOIUrl":"10.1016/S2589-5559(25)00181-8","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 7","pages":"Article 101503"},"PeriodicalIF":9.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144572391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Board page","authors":"","doi":"10.1016/S2589-5559(25)00178-8","DOIUrl":"10.1016/S2589-5559(25)00178-8","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 7","pages":"Article 101500"},"PeriodicalIF":9.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144572389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-based differences in survival after liver transplantation for colorectal cancer liver metastases: A multivariable analysis","authors":"Alessandro Vitale ,&nbsp;Jacopo Lanari ,&nbsp;Umberto Cillo ,&nbsp;Ilaria Billato ,&nbsp;Alessandro Rovetta ,&nbsp;Mohammad Ali Mansournia ,&nbsp;Matteo Cescon ,&nbsp;Matteo Serenari ,&nbsp;Federico Aucejo ,&nbsp;Bassam Estfan ,&nbsp;Laurent Coubeau ,&nbsp;Samuele Iesari ,&nbsp;Vincenzo Mazzaferro ,&nbsp;Carlo Sposito ,&nbsp;Roberto Hernandez-Alejandro ,&nbsp;Koji Tomiyama ,&nbsp;Morten Hagness ,&nbsp;Svein Dueland ,&nbsp;Pål Dag Line","doi":"10.1016/j.jhepr.2025.101505","DOIUrl":"10.1016/j.jhepr.2025.101505","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Liver transplantation (LT) for colorectal liver metastases (CRLMs) is attracting increasing interest, especially after publication of the TransMet trial. However, multivariable survival analyses are lacking. Here, we performed such an analysis in a multicentre cohort.</div></div><div><h3>Methods</h3><div>We conducted a retrospective multicentre study of 82 patients with CRLMs undergoing LT (from 2006 to 2020) across seven US and European centres, using multivariable Cox, competing-risk models, and extensive sensitivity analyses.</div></div><div><h3>Results</h3><div>Overall survival rates after 1, 3, and 5 years were 93.7%, 73.4%, and 54.9%, respectively. The findings align with an association between higher risk and the female sex (estimated hazard ratio (HR) 4.1, 95% CI: 1.8–9.2), and the following variables: carcinoembryonic antigen &gt;80 μg/L, right-located colorectal cancer (CRC), largest diameter &gt;5.5 cm, KRAS mutation, and absence of previous liver therapy. Other possible associations with higher uncertainty were pN2-positive CRC and the number of nodules (&gt;10). Variables such as progressive disease after pretransplant chemotherapy and time from primary CRC surgery to LT of ≤24 months, exhibited weaker, less consistent associations.</div></div><div><h3>Conclusions</h3><div>This first multivariable survival analysis of LT for CRLM suggests that female sex is associated with worse outcomes, whereas the prognostic strength of the model currently used in clinical practice is not confirmed. Our findings challenge current selection criteria, highlighting the need for improved prognostic models with better discrimination and calibration.</div></div><div><h3>Impact and implications</h3><div>This multicentre retrospective study analysed survival outcomes in 82 patients undergoing liver transplantation for colorectal liver metastases across seven US and European centres. Several factors, including female sex, high carcinoembryonic antigen levels, right-sided colorectal cancer, larger tumours, KRAS mutation, pN2-positive CRC, number of nodules, and no prior liver therapy, were linked to poorer outcomes. The study questions current prognostic models and selection criteria, emphasizing the need for more accurate tools to guide decision-making in patients with colorectal liver metastases.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 10","pages":"Article 101505"},"PeriodicalIF":7.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy","authors":"Pei-Chang Lee ,&nbsp;Chi-Jung Wu ,&nbsp;I-Cheng Lee ,&nbsp;Chieh-Ju Lee ,&nbsp;Ming-Chih Hou ,&nbsp;Yi-Hsiang Huang","doi":"10.1016/j.jhepr.2025.101491","DOIUrl":"10.1016/j.jhepr.2025.101491","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Most patients with hepatocellular carcinoma (HCC) have underlying chronic liver disease, which may influence survival outcomes. Mac-2 binding protein glycosylation isomer (M2BPGi) is a biomarker reflecting liver fibrosis status, which in turn may be associated with survival in patients with HCC treated with immune checkpoint inhibitors (ICIs), particularly in regions where viral hepatitis is endemic.</div></div><div><h3>Methods</h3><div>From September 2017 to September 2022, 158 patients receiving ICIs for unresectable HCC were prospectively enrolled, and baseline serum samples were collected for M2BPGi measurement. Variables associated with overall survival (OS) were analyzed. An additional 60 consecutive patients with unresectable HCC were recruited after October 2022 for validation.</div></div><div><h3>Results</h3><div>In the training cohort, serum M2BPGi level correlated strongly with Fibrosis-4 score, Child-Pugh class and ALBI (albumin-bilirubin) grade. An M2BPGi ≥1.68 COI (cut-off index) was associated with significantly reduced OS (hazard ratio 1.992, 95% CI 1.369–2.900; <em>p</em> &lt;0.001). By incorporating baseline alpha-fetoprotein (≥100 ng/ml), M2BPGi (≥1.68 COI), portal vein invasion, and non-HBV infection, a new Mac-2 score was developed that effectively stratified patients by OS (28.8, 13.6 and 8.3 months for scores of 0-1, 2 and 3-4, respectively, <em>p</em> &lt;0.001). The Mac-2 score demonstrated superior discrimination and calibration abilities (the highest AUROC, greatest homogeneity, and the lowest corrected Akaike information criterion value), and net reclassification improvement compared with the CRAFITY score, ALBI grade, and Child-Pugh class.</div></div><div><h3>Conclusion</h3><div>Serum fibrosis marker M2BPGi correlates with liver reserves and survival in patients with HCC undergoing ICI-based immunotherapy. The newly developed Mac-2 score may offer improved clinical utility in this population.</div></div><div><h3>Impact and implications</h3><div>Most cases of hepatocellular carcinoma occur in patients with underlying liver fibrosis or cirrhosis, and the fibrotic microenvironment may influence the anti-tumor effects of immune checkpoint inhibitors. Serum M2BPGi reflects liver fibrosis status and liver reserve in hepatocellular carcinoma and is associated with survival outcomes in patients receiving ICI-based immunotherapy. The novel Mac-2 score, based on baseline M2BPGi levels, has the potential to enhance patient selection and guide therapeutic strategies.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 9","pages":"Article 101491"},"PeriodicalIF":7.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy.","authors":"Yu Chen, Haoyu Wen, You Li, Weituo Zhang, Tianyu Mao, Chenyi Jiang, Huayang Zhang, Yujie Zhou, Xiting Pu, Bo Li, Jun Zhang, Li Yan, Min Lian, Li Sheng, Canjie Guo, Qixia Wang, Qi Miao, Jing Hua, Hai Li, Ruqi Tang, Christopher L Bowlus, M Eric Gershwin, Zhengrui You, Xiao Xiao, Xiong Ma","doi":"10.1016/j.jhepr.2025.101496","DOIUrl":"10.1016/j.jhepr.2025.101496","url":null,"abstract":"<p><strong>Background & aims: </strong>In this study, we aimed to evaluate the incidence, predictors, and prognostic significance of recompensation in autoimmune hepatitis (AIH)-related decompensated cirrhosis following immunosuppressive therapy (IST).</p><p><strong>Methods: </strong>We retrospectively analyzed patients with AIH at first decompensation. Recompensation, defined using modified Baveno VII criteria, required clinical resolution (≥12 months without ascites, variceal bleeding, or hepatic encephalopathy, with liver function restored to Child-Pugh A) along with aetiological suppression (complete biochemical response under IST). Predictors of recompensation were identified using multivariate regression, and survival outcomes were compared among compensated, recompensated, and non-recompensated groups.</p><p><strong>Results: </strong>A total of 258 patients with AIH-related decompensated cirrhosis were included (median follow-up: 47 months, IQR 28-75). Clinical resolution was achieved by 124 patients (48.1%), while 68 patients (30.9% of 220 treated with IST) met criteria for recompensation. Predictors of recompensation included ascites as the only complication (hazard ratio [HR] 14.40, 95% CI 4.17-49.64, <i>p <</i>0.001), lower IgG levels (HR 0.90, 95% CI 0.89-0.96, <i>p <</i>0.001), higher bilirubin levels (HR 1.04, 95% CI 1.00-1.08, <i>p</i> = 0.030), and higher platelet counts (HR 1.01, 95% CI 1.00-1.01, <i>p</i> = 0.039). Patients achieving recompensation experienced a significantly reduced risk of liver transplantation or death (HR 0.07, 95% CI 0.01-0.50, <i>p</i> = 0.009), with survival outcomes comparable to those of compensated patients.</p><p><strong>Conclusions: </strong>Recompensation was achieved in approximately one-third of patients with AIH-related decompensated cirrhosis undergoing IST, leading to markedly improved transplant-free survival. Predictors of recompensation included having ascites as the sole complication, lower IgG levels, higher bilirubin levels, and higher platelet counts.</p><p><strong>Impact and implications: </strong>The predictors and long-term prognostic implications of recompensation in patients with autoimmune hepatitis (AIH)-related decompensated cirrhosis remain unclear. This study demonstrates that recompensation is achievable in patients with AIH-related decompensated cirrhosis and is associated with significant long-term benefits, including improved survival and reduced transplantation needs. We identified ascites (as the sole decompensating event), lower IgG levels, higher bilirubin levels and higher platelet counts as independent predictors of recompensation. These findings can be used by clinicians to identify the patients most likely to benefit from immunosuppressive therapy.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 9","pages":"101496"},"PeriodicalIF":7.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restoration of the gut-microbiota-liver axis after hepatitis C virus eradication.","authors":"Takako Inoue, Jiro Nakayama, Hiroshi Mori, Masaru Tanaka, Daisuke Nakagawa, Masaya Ohnishi, Yui Funatsu, Kei Moriya, Hideto Kawaratani, Hisayoshi Watanabe, Goki Suda, Yasuteru Kondo, Tatsuya Ide, Satoru Kakizaki, Satoshi Miuma, Atsushi Suetsugu, Kazuhito Kawata, Takao Watanabe, Etsuko Iio, Rie Momoda, Yutaka Suzuki, Akira Sakamaki, Tsunamasa Watanabe, Takehisa Watanabe, Katsuya Nagaoka, Yoichi Hiasa, Shuji Terai, Hitoshi Yoshiji, Atsushi Toyoda, Ken Kurokawa, Yasuhito Tanaka","doi":"10.1016/j.jhepr.2025.101494","DOIUrl":"10.1016/j.jhepr.2025.101494","url":null,"abstract":"<p><strong>Background & aims: </strong>We previously reported altered intestinal environmental features during HCV infection. Here, we aimed to characterize the gut-microbiota-liver axis in patients with chronic hepatitis C after a sustained virological response (SVR).</p><p><strong>Methods: </strong>A total of 174 patients with HCV infection were enrolled in a cross-sectional study: 95 with chronic hepatitis (CH-HCV group) and 79 with cirrhosis or hepatocellular carcinoma (LC/HCC-HCV group). In addition, 75 post-SVR patients were included (CH-SVR group, n = 29; LC/HCC-SVR group, n = 46), along with 23 healthy individuals. A longitudinal study was subsequently conducted on 49 patients (CH, n = 29; LC/HCC, n = 20) with SVR at 24 and 48 weeks after the end of treatment. RNA sequencing was performed on 65 patients with HCV infection, 28 post-SVR patients, and 12 healthy controls.</p><p><strong>Results: </strong>In the cross-sectional analysis, HCV eradication was associated with partial restoration of the dysbiotic gut microbiota, including reduced streptococcal overgrowth and an increase in the potentially beneficial genus <i>Blautia</i>, approaching levels seen in healthy individuals. Additionally, the aberrant fecal bile acid profile showed rebalancing, accompanied by restored expression of genes involved in the classical pathway of cholic and chenodeoxycholic acid biosynthesis. In the longitudinal study, improvements in liver fibrosis and function - evidenced by decreased Fibrosis-4 index and alanine aminotransferase levels - were significantly correlated with increased abundance of Blautia (<i>p</i> <0.0001 and <i>p</i> = 0.0344, respectively), suggesting a beneficial role in liver recovery.</p><p><strong>Conclusion: </strong>The gut-microbiota-liver axis is partially restored following HCV eradication, with recovery from liver damage associated with the resurgence of commensal Lachnospiraceae species.</p><p><strong>Impact and implications: </strong>This study offers significant insights into the gut-microbiota-liver axis in patients with chronic hepatitis C following a sustained virological response. The findings demonstrate that HCV eradication promotes partial restoration of the dysbiotic gut microbiota, particularly an increase in the beneficial genus <i>Blautia</i>, as well as a rebalancing of the fecal bile acid profile. These changes are closely associated with significant improvements in liver fibrosis and function, highlighting a potential role of the gut microbiota in liver recovery and regeneration.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 9","pages":"101494"},"PeriodicalIF":7.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: \"Statins in MASLD: Challenges and future directions\".","authors":"Vivian D de Jong, Stella Trompet, J Wouter Jukema, Diederick E Grobbee, Manuel Castro Cabezas","doi":"10.1016/j.jhepr.2025.101490","DOIUrl":"10.1016/j.jhepr.2025.101490","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 9","pages":"101490"},"PeriodicalIF":7.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cholangiocarcinoma in Denmark: Time-trends in incidence and mortality","authors":"Morten Daniel Jensen ,&nbsp;Joe West ,&nbsp;Britta Weber ,&nbsp;Frank Viborg Mortensen ,&nbsp;Peter Jepsen","doi":"10.1016/j.jhepr.2025.101493","DOIUrl":"10.1016/j.jhepr.2025.101493","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Cholangiocarcinomas have a poor prognosis, and the incidence is rising in most countries. We examined time-trends in incidence and mortality in a nationwide Danish cohort.</div></div><div><h3>Methods</h3><div>We used nationwide health databases to identify all Danish citizens diagnosed with cholangiocarcinoma from 1995 to 2022. We computed age-standardised incidence rates, stage distribution, and age- and sex-adjusted 1-year mortality.</div></div><div><h3>Results</h3><div>The median age of the 5,787 patients with cholangiocarcinoma was 72 years, and 53% were female. Overall, the age-standardised incidence rate per 100,000 person-years almost doubled, from 3.93 (95% CI 3.59-4.26) in 1995-1998 to 6.79 (6.42-7.16) in 2019-2022. This rate increased five-fold for intrahepatic cholangiocarcinoma from 0.75 (0.61-0.90) in 1995-1998 to 3.85 (3.57-4.13) in 2019-2022, while for extrahepatic cholangiocarcinoma it decreased from 2.42 (2.16-2.69) in 1995-1998 to 1.30 (1.14-1.47) in 2019-2022. Although individuals aged 18–59 years had the lowest incidence rate of cholangiocarcinoma (any type), they experienced the steepest annual increase (3.2% <em>vs.</em> 2.7% in those aged 60–79 and 2.1% in those ≥80 years; <em>p</em> for interaction = 0.01). Among all patients with cholangiocarcinoma, the proportion with localised resectable disease increased from 7% in 2004-2006 to 12% in 2019-2022. We saw a decrease in age- and sex-adjusted 1-year mortality between 1995 and 2022: 81% (77-84) in 1995-1998 <em>vs</em>. 65% (63-68) in 2019-2022. The decrease in 1-year mortality was universal, with the largest decrease in patients aged 18–59 years (from 67% in 1995-1998 to 49% in 2019-2022) and in 60-79-year-olds.</div></div><div><h3>Conclusion</h3><div>The incidence of cholangiocarcinoma in Denmark increased in 1995-2022, driven by an increasing incidence of intrahepatic cholangiocarcinoma. Meanwhile, 1-year mortality decreased, likely reflecting earlier diagnosis and better treatments.</div></div><div><h3>Impact and implications</h3><div>Cholangiocarcinomas have a poor prognosis, and the incidence is rising in most countries. In Europe, all countries but Denmark have shown an increasing incidence of intrahepatic cholangiocarcinoma. The incidence of cholangiocarcinoma in Denmark between 1995 and 2022 increased, driven by a large increase in intrahepatic cholangiocarcinomas. The proportion with localised resectable disease increased while 1-year mortality decreased, though it remained high (65% in 2019-2022). Knowledge of incidence and mortality risk is valuable for doctors to understand the disease, identify risk factors, and design preventive care studies; for healthcare providers to allocate resources; and for patients to understand their prognosis.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 9","pages":"Article 101493"},"PeriodicalIF":7.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}